Macrogenics (MGNX) Net Income towards Common Stockholders (2012 - 2026)

Macrogenics (MGNX) has 15 years of Net Income towards Common Stockholders data on file, last reported at -$38.9 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 8.91% year-over-year to -$38.9 million in Q1 2026; TTM through Mar 2026 was -$72.5 million, a 26.04% decrease from a year earlier, with the FY2025 full-year figure at -$74.6 million, down 11.39% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$38.9 million, down from -$14.1 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for MGNX reached as high as $56.3 million in Q3 2024 and fell as low as -$100.2 million in Q1 2024.
• Historically, Net Income towards Common Stockholders has averaged -$31.2 million across 5 years, with a median of -$38.9 million in 2026.
• Across the five-year window, Net Income towards Common Stockholders slumped 511.87% in 2023 and soared 258.61% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $12.0 million in 2022, then slumped by 511.87% to -$49.4 million in 2023, then surged by 68.75% to -$15.4 million in 2024, then grew by 8.39% to -$14.1 million in 2025, then tumbled by 175.42% to -$38.9 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$38.9 million in Q1 2026, -$14.1 million in Q4 2025, and $16.8 million in Q3 2025.